CBAY - Cymabay Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue10,000--
Cost of Revenue---
Gross Profit10,000--
Operating Expenses
Research Development18,93815,94117,026
Selling General and Administrative12,3879,6458,871
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-21,325-25,586-25,897
Income from Continuing Operations
Total Other Income/Expenses Net-5,15225211,281
Earnings Before Interest and Taxes-26,477-25,334-14,616
Interest Expense1,0801,337913
Income Before Tax-27,557-26,671-15,529
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-27,557-26,671-15,529
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-27,557-26,671-15,529
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-27,557-26,671-15,529